The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer
- 1 July 1996
- journal article
- Published by Elsevier in International Journal of Radiation Oncology*Biology*Physics
- Vol. 35 (4) , 669-677
- https://doi.org/10.1016/0360-3016(96)00185-x
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Use of tamoxifen for breast cancer: twenty-eight years later.Journal of Clinical Oncology, 1995
- Adjuvant systemic chemotherapy and hormonal therapy. Effect on local recurrence in the conservatively treated breast cancer patientCancer, 1994
- Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trialsWorld Journal of Surgery, 1994
- Adjuvant tamoxifen versus placebo in elderly women with node-positive breast cancer: long-term follow-up and causes of death.Journal of Clinical Oncology, 1993
- Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapyThe Lancet, 1992
- A Randomized Clinical Trial Evaluating Tamoxifen in the Treatment of Patients with Node-Negative Breast Cancer Who Have Estrogen-Receptor–Positive TumorsNew England Journal of Medicine, 1989
- Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancerBritish Journal of Cancer, 1988
- Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06.Journal of Clinical Oncology, 1988
- The pharmacology and clinical uses of tamoxifenPharmacology & Therapeutics, 1984
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958